AMAG Pharmaceuticals Price Target Cut to $23.00 by Analysts at Ladenburg Thalmann (AMAG)

Share on StockTwits

Equities research analysts at Ladenburg Thalmann lowered their price target on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) from $25.00 to $23.00 in a research note issued to investors on Monday, Analyst Ratings Network.com reports. Ladenburg Thalmann’s price objective suggests a potential upside of 15.87% from the stock’s previous close.

Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) traded up 0.49% during mid-day trading on Monday, hitting $20.50. AMAG Pharmaceuticals has a one year low of $12.43 and a one year high of $23.98. The stock’s 50-day moving average is currently $21.49. The company’s market cap is $442.3 million.

AMAG Pharmaceuticals (NASDAQ: AMAG) last posted its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.18) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.02. The company had revenue of $17.90 million for the quarter, compared to the consensus estimate of $17.99 million. During the same quarter last year, the company posted ($0.58) earnings per share. AMAG Pharmaceuticals’s revenue was up 15.5% compared to the same quarter last year. Analysts expect that AMAG Pharmaceuticals will post $-0.63 EPS for the current fiscal year.

Separately, analysts at Jefferies Group raised their price target on shares of AMAG Pharmaceuticals from $12.00 to $14.00 in a research note to investors on Thursday, April 25th. They now have an “underperform” rating on the stock.

One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $18.20.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ: AMAG).

Latest News

Best Buy Stock Up on Earnings Report
Best Buy Stock Up on Earnings Report
FTC and Credit Score Firm Settle Charges
FTC and Credit Score Firm Settle Charges
Xiaomi Share Values IQiyi at $3 Billion
Xiaomi Share Values IQiyi at $3 Billion
Nokia Returns to Consumer Electronics with Android Tablet
Nokia Returns to Consumer Electronics with Android Tablet
Actavis Close to Deal to Acquire Allergan for $64 Billion
Actavis Close to Deal to Acquire Allergan for $64 Billion
Earnings Season Ends This Week with Retailers
Earnings Season Ends This Week with Retailers


Leave a Reply

Advertisement
Advertisement
© 2006-2014 Ticker Report. Google+.